---
title: "Kanion Pharmaceutical released its 2024 annual performance, with a net profit attributable to the parent company of 392 million yuan, a year-on-year decrease of 15.58%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/234203950.md"
description: "According to the Zhitong Finance APP, Kanion Pharmaceutical released its 2024 annual report, stating that the company's operating revenue for 2024 is 3.898 billion yuan, a year-on-year decrease of 19.86%; the net profit attributable to shareholders of the listed company is 392 million yuan, a year-on-year decrease of 15.58%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses is 363 million yuan, a year-on-year decrease of 27.29%; the basic earnings per share is 0.68 yuan/share"
datetime: "2025-04-02T10:46:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/234203950.md)
  - [en](https://longbridge.com/en/news/234203950.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/234203950.md)
generator: "portal-rs"
---

# Kanion Pharmaceutical released its 2024 annual performance, with a net profit attributable to the parent company of 392 million yuan, a year-on-year decrease of 15.58%

According to the Zhitong Finance APP, Kanion Pharmaceutical (600557.SH) released its 2024 annual report, stating that the company's operating revenue for 2024 was 3.898 billion yuan, a year-on-year decrease of 19.86%; the net profit attributable to shareholders of the listed company was 392 million yuan, a year-on-year decrease of 15.58%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 363 million yuan, a year-on-year decrease of 27.29%; the basic earnings per share was 0.68 yuan/share

### Related Stocks

- [600557.CN](https://longbridge.com/en/quote/600557.CN.md)

## Related News & Research

- [SynAct Pharma bolsters resomelagon data as it readies Phase 3 and weighs strategic deals](https://longbridge.com/en/news/298195637.md)
- [Taiwan's HORIEN Accelerates Global Footprint: Achieves Three Thai FDA Class 4 Approvals and Secures U.S. Patent for Biodegradable Ureteral Stent](https://longbridge.com/en/news/298248769.md)
- [Philippines Central Bank Weighs Freeze On New Payment Operator Licenses](https://longbridge.com/en/news/298229616.md)
- [mPay Switches Regulated Payment Partner to Meest Transfer](https://longbridge.com/en/news/298227078.md)
- [Mabwell reports Phase Ib/IIa data showing anti-ST2 antibody 9MW1911 cuts COPD exacerbations up to 81%](https://longbridge.com/en/news/298042457.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**